As knowledge on NAMPT involvement in cancer pathobiology is continuously evolving [38], we have focused on the role of the novel DAMP, eNAMPT, a key immunity and metabolic regulator involving diverse physiological and pathological processes [21,22,34,38,39,40] and a highly druggable therapeutic target, in preventing aggressive PCa progression [12]. This evidence concerns the gene NAMPT and posterior cortical atrophy.